Executive Management


– Dr. Zocca has served as our founder and Chief Executive Officer since January 2015. Dr. Zocca was also the founder and Chief Executive Officer of OncoNOx ApS, a pharmaceutical company, from July 2011 until May 2019. Prior to founding the Company, she was the Chief Executive Officer at LevOss ApS, a biotechnology company, from January 2012 until January 2017. Dr. Zocca also led DanDrit Biotech A/S, a biotechnology company, as its Chief Executive Officer from July 2007 until December 2010. Dr. Zocca currently serves on the board of directors for Dansk Biotek, a Danish biotechnology trade organization, and Valo Therapeutics Ltd., a biotechnology company. Dr. Zocca received her M.Sc in Biochemistry as well as Ph.D. in Medicine from the University of Copenhagen and NIH, NCI, MD, US.


Ms. Sullivan is a seasoned life sciences professional with more than 25 years of experience raising capital and building and managing corporate biotechnology and life sciences brands. Ms. Sullivan joins IO Biotech from TABA, BV, where she served as chief financial officer.

Prior to her time with TABA, Ms. Sullivan was chief strategy office for Euronext-listed Kiadis Pharma where she was responsible for all aspects of fundraising and capital formation strategy, repositioning the company after a clinical failure, and played a critical role in the company’s sale to Sanofi.

Prior to Kiadis, Ms. Sullivan served Keryx Biopharmaceuticals where she was senior vice president of corporate affairs, responsible for all aspects of investor relations, corporate communication, and public affairs, during a period of high growth, commercialization of the company’s first FDA-approved medicine and, ultimately, a merger. Prior to Keryx, Ms. Sullivan served as head of corporate communications and investor relations at AMAG Pharmaceuticals, Idenix Biopharmacueticals and Genencor International.

Earlier in her career, Ms. Sullivan served in roles of increasing responsibility in both agencies and Fortune 500 companies. Ms. Sullivan has her bachelor of science degree in business from Salem State University and her master's of business administration from Bentley University.


Dr. Ehrnrooth has served as our Chief Medical Officer since October 2017. Prior to this, she joined Boehringer Ingelheim, a pharmaceutical company, in 2010 and served as its Global 168Clinical Program Team Leader until October 2017. Dr. Ehrnrooth has extensive experience in the oncology field. She was a Senior Scientist, Medical Director, Oncology at Novo Nordisk A/S, a pharmaceutical company, from June 2006 until May 2008 and was Medical Director, Oncology at Genmab A/S, a biotechnology company, from June 2008 until February 2010. Dr. Ehrnrooth received her M.D. and Ph.D. in Medicine from Aarhus University.


Mr. Smith join IO Biotech in January 2023, bringing more than 25 years of legal and compliance experience serving clients in the life science industries. Mr. Smith joins IO Biotech from Yumanity Therapeutics, Inc., a publicly traded biotechnology company, where he served as Senior Vice President and General Counsel.

At Yumanity, he helped lead the sale of the company’s neuroscience assets to Johnson & Johnson and a reverse merger with a privately held oncology immunotherapy company. Prior to Yumanity, Mr. Smith served as Senior Vice President and General Counsel of Minerva Neurosciences, Inc., where he was responsible for all legal, governance and compliance matters, and led the sale of potential royalties to Royalty Pharma for upfront and potential milestone payments of $155 million.

Before joining Minerva, Mr. Smith served as General Counsel of Stallergenes Greer plc, a publicly traded, global biopharmaceutical company focused on allergy immunotherapy products. Previously, Mr. Smith led the North American legal department for EMD Serono, Inc., the biopharmaceutical division of Merck KGaA. Mr. Smith received his J.D. from Suffolk University Law School and his bachelor’s degree from the University of North Carolina – Chapel Hill.